These insights into the intricate regulatory mechanisms involving Mcl-1 and its interplay with various signaling and ubiquitin pathways emphasize the significant potential for targeted therapies that can enhance the efficacy of BH3 mimetic drugs and overcome resistance, ultimately improving cancer treatment outcomes. This evidence concerns the gene MCL1 and cancer.